세계의 맥락막 신생혈관 시장 보고서(2025년)

Choroidal neovascularization (CNV) is the abnormal growth of blood vessels in the choroid layer of the eye, often extending into the retina. These newly formed blood vessels are fragile and prone to leaking fluid or blood, which can damage retinal tissues and lead to vision distortion or loss.

The main treatment options for choroidal neovascularization include anti-angiogenic therapy, laser photocoagulation, photodynamic therapy, verteporfin sodium, ranibizumab, bevacizumab, aflibercept, and pegaptanib sodium. Anti-angiogenic therapy works by inhibiting the formation of new blood vessels (angiogenesis), helping to prevent the growth of abnormal blood vessels. These treatments are commonly used for specific conditions such as age-related macular degeneration (AMD), diabetic macular edema (DME), central serous chorioretinopathy (CSC), polypoidal choroidal vasculopathy (PCV), myopic macular degeneration (MMD), and other related conditions. The administration route may vary, including intravitreal, subconjunctival, periocular, or oral methods. These therapies are primarily administered in hospitals, ophthalmology clinics, and ambulatory surgical centers.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.

The choroidal neovascularization market research report is one of a series of new reports from The Business Research Company that provides choroidal neovascularization market statistics, including the choroidal neovascularization industry global market size, regional shares, competitors with the choroidal neovascularization market share, detailed choroidal neovascularization market segments, market trends, and opportunities, and any further data you may need to thrive in the choroidal neovascularization industry. This choroidal neovascularization market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The choroidal neovascularization market size has grown strongly in recent years. It will grow from $3.88 billion in 2024 to $4.18 billion in 2025 at a compound annual growth rate (CAGR) of 7.7%. The growth in the historic period can be attributed to the growing prevalence of sedentary lifestyle diseases, increasing prevalence of age-related macular degeneration, rising incidence of retinal illnesses, rising aged population, rising eye care costs, and expanding education and screening initiatives.

The choroidal neovascularization market size is expected to see strong growth in the next few years. It will grow to $5.59 billion in 2029 at a compound annual growth rate (CAGR) of 7.5%. The growth in the forecast period can be attributed to increasing patient awareness, growing adoption of optical coherence tomography angiography, growing demand for minimally invasive procedures, favorable reimbursement policies, and a growing geriatric population. Major trends in the forecast period include the emergence of intravitreal anti-vascular endothelial (VEGF) therapies, new gene treatments, gene therapy approaches, the adoption of telemedicine, the development of combination therapies, and personalized treatment strategies.

The forecast of 7.5% growth over the next five years reflects a slight reduction of 0.2% from the previous projection. This reduction is primarily due to the impact of tariffs between the US and other countries. Trade tensions could hinder U.S. ophthalmology by inflating prices of anti-vascular endothelial growth factor(anti-VEGF) injections and optical coherence tomography systems developed in Japan and Germany, resulting in delayed age-related macular degeneration(AMD) treatment and higher retinal specialty costs. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The increasing prevalence of age-related macular degeneration (AMD) is expected to drive the growth of the choroidal neovascularization (CNV) market in the future. AMD is an eye condition that gradually damages the macula, resulting in central vision loss, particularly among older adults. The rising prevalence of AMD is attributed to factors such as an aging population, increased life expectancy, lifestyle changes, genetic influences, and increased exposure to environmental risks. CNV plays a significant role in wet AMD, where abnormal blood vessel growth beneath the retina leads to vision deterioration. Advanced treatments such as anti-VEGF therapy are used to manage CNV, slow the progression of AMD, and help preserve central vision in affected individuals. For example, in September 2022, the National Institutes of Health projected that by 2040, AMD cases may reach 300 million, and by 2050, 5.4 million Americans could be affected. Therefore, the rising prevalence of AMD is driving the growth of the CNV market.

Leading companies in the CNV market are focusing on developing innovative treatments, such as photodynamic therapy (PDT), to provide eye care professionals with more precise and effective options that enhance patient outcomes and treatment delivery. PDT uses a photosensitizing agent activated by light to target and destroy abnormal or cancerous cells. For instance, in February 2023, Bausch & Lomb, a Canada-based healthcare company, and Modulight, a Finland-based biomedical company, announced the approval of the ML6710i photodynamic laser by the U.S. Food and Drug Administration. This therapy is used in conjunction with Bausch + Lomb's VISUDYNE therapy to treat CNV caused by AMD. The advanced, mobile ophthalmic laser offers a targeted approach to treating abnormal blood vessels in the eye, helping to prevent further disease progression and preserve vision.

In March 2024, Sandoz Group AG, a Switzerland-based pharmaceutical company, acquired the CIMERLI business from Coherus for $170 million. With this acquisition, Sandoz aims to expand its portfolio in the ophthalmic sector, strengthening its ability to offer innovative treatments for retinal diseases, such as AMD. Coherus BioSciences, a U.S.-based biopharmaceutical company, focuses on the research and development of treatments for diseases such as CNV.

Major players in the choroidal neovascularization market are Pfizer Inc., Roche Holding AG, AbbVie Inc., Bayer Aktiengesellschaft, Novartis AG, Teva Pharmaceutical Industries Limited, Regeneron Pharmaceuticals Inc., Astellas Pharma Inc., Biogen Inc., Chugai Pharmaceutical Co. Ltd., Alcon Inc., Genentech Inc., Bausch + Lomb Incorporated, Samsung Bioepis Co. Ltd., Santen Pharmaceutical Co. Ltd., Apellis Pharmaceuticals Inc., Kodiak Sciences Inc., Xbrane Biopharma AB, Allergan Inc., Adverum Biotechnologies Inc., Clearside Biomedical Inc., Sylentis S.A.

North America was the largest region in the choroidal neovascularization market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in choroidal neovascularization report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the choroidal neovascularization market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The choroidal neovascularization market consists of revenues earned by entities by providing services such as diagnostic services, therapeutic services, and follow-up and monitoring services. The market value includes the value of related goods sold by the service provider or included within the service offering. The choroidal neovascularization market also includes sales of injections, therapy agents, and surgical & laser devices. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Choroidal Neovascularization Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on choroidal neovascularization market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for choroidal neovascularization ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The choroidal neovascularization market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Treatment Type: Anti-Angiogenic Therapy; Laser Photocoagulation; Photodynamic Therapy; Verteporfin Sodium; Ranibizumab; Bevacizumab; Aflibercept; Pegaptanib Sodium
• 2) By Indication: Age-Related Macular Degeneration (AMD); Diabetic Macular Edema (DME); Central Serous Chorioretinopathy (CSC); Polypoidal Choroidal Vasculopathy (PCV); Myopic Macular Degeneration (MMD); Other Indications
• 3) By Route Of Administration: Intravitreal; Subconjunctival; Periocular; Oral
• 4) By End User: Hospitals; Ophthalmology Clinics; Ambulatory Surgical Centers; Research Centers
• Subsegments:
• 1) By Anti-Angiogenic Therapy (Anti-VEGF Therapy): Ranibizumab; Bevacizumab; Aflibercept; Pegaptanib Sodium
• 2) By Laser Photocoagulation: Thermal Laser Photocoagulation; MicroPulse Laser Therapy
• 3) By Photodynamic Therapy (PDT): Standard PDT; Low-Fluence PDT; Half-Dose PDT
• 4) By Verteporfin Sodium: Intravenous Administration; Combination Therapy With Anti-VEGF
• 5) By Ranibizumab: Monthly Dosing; As-Needed Dosing; Treat-and-Extend Regimen
• 6) By Bevacizumab: Off-Label Use; Compounded Intravitreal Injections
• 7) By Aflibercept: Fixed-Dosing Regimen; Treat-and-Extend Regimen
• 8) By Pegaptanib Sodium: Monotherapy; Combination Therapy
• Companies Mentioned: Pfizer Inc.; Roche Holding AG; AbbVie Inc.; Bayer Aktiengesellschaft; Novartis AG; Teva Pharmaceutical Industries Limited; Regeneron Pharmaceuticals Inc.; Astellas Pharma Inc.; Biogen Inc.; Chugai Pharmaceutical Co. Ltd.; Alcon Inc.; Genentech Inc.; Bausch + Lomb Incorporated; Samsung Bioepis Co. Ltd.; Santen Pharmaceutical Co. Ltd.; Apellis Pharmaceuticals Inc.; Kodiak Sciences Inc.; Xbrane Biopharma AB; Allergan Inc.; Adverum Biotechnologies Inc.; Clearside Biomedical Inc.; Sylentis S.A.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Choroidal Neovascularization Market Characteristics

3. Choroidal Neovascularization Market Trends And Strategies

4. Choroidal Neovascularization Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

• 4.1. Supply Chain Impact from Tariff War & Trade Protectionism

5. Global Choroidal Neovascularization Growth Analysis And Strategic Analysis Framework

• 5.1. Global Choroidal Neovascularization PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Choroidal Neovascularization Market Growth Rate Analysis
• 5.4. Global Choroidal Neovascularization Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Choroidal Neovascularization Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Choroidal Neovascularization Total Addressable Market (TAM)

6. Choroidal Neovascularization Market Segmentation

• 6.1. Global Choroidal Neovascularization Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Anti-Angiogenic Therapy
• Laser Photocoagulation
• Photodynamic Therapy
• Verteporfin Sodium
• Ranibizumab
• Bevacizumab
• Aflibercept
• Pegaptanib Sodium
• 6.2. Global Choroidal Neovascularization Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Age-Related Macular Degeneration (AMD)
• Diabetic Macular Edema (DME)
• Central Serous Chorioretinopathy (CSC)
• Polypoidal Choroidal Vasculopathy (PCV)
• Myopic Macular Degeneration (MMD)
• Other Indications
• 6.3. Global Choroidal Neovascularization Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Intravitreal
• Subconjunctival
• Periocular
• Oral
• 6.4. Global Choroidal Neovascularization Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Ophthalmology Clinics
• Ambulatory Surgical Centers
• Research Centers
• 6.5. Global Choroidal Neovascularization Market, Sub-Segmentation Of Anti-Angiogenic Therapy (Anti-VEGF Therapy), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Ranibizumab
• Bevacizumab
• Aflibercept
• Pegaptanib Sodium
• 6.6. Global Choroidal Neovascularization Market, Sub-Segmentation Of Laser Photocoagulation, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Thermal Laser Photocoagulation
• MicroPulse Laser Therapy
• 6.7. Global Choroidal Neovascularization Market, Sub-Segmentation Of Photodynamic Therapy (PDT), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Standard PDT
• Low-Fluence PDT
• Half-Dose PDT
• 6.8. Global Choroidal Neovascularization Market, Sub-Segmentation Of Verteporfin Sodium, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Intravenous Administration
• Combination Therapy With Anti-VEGF
• 6.9. Global Choroidal Neovascularization Market, Sub-Segmentation Of Ranibizumab, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Monthly Dosing
• As-Needed Dosing
• Treat-and-Extend Regimen
• 6.10. Global Choroidal Neovascularization Market, Sub-Segmentation Of Bevacizumab, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Off-Label Use
• Compounded Intravitreal Injections
• 6.11. Global Choroidal Neovascularization Market, Sub-Segmentation Of Aflibercept, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Fixed-Dosing Regimen
• Treat-and-Extend Regimen
• 6.12. Global Choroidal Neovascularization Market, Sub-Segmentation Of Pegaptanib Sodium, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Monotherapy
• Combination Therapy

7. Choroidal Neovascularization Market Regional And Country Analysis

• 7.1. Global Choroidal Neovascularization Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Choroidal Neovascularization Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Choroidal Neovascularization Market

• 8.1. Asia-Pacific Choroidal Neovascularization Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Choroidal Neovascularization Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Choroidal Neovascularization Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Choroidal Neovascularization Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Choroidal Neovascularization Market

• 9.1. China Choroidal Neovascularization Market Overview
• 9.2. China Choroidal Neovascularization Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Choroidal Neovascularization Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Choroidal Neovascularization Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Choroidal Neovascularization Market

• 10.1. India Choroidal Neovascularization Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Choroidal Neovascularization Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Choroidal Neovascularization Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Choroidal Neovascularization Market

• 11.1. Japan Choroidal Neovascularization Market Overview
• 11.2. Japan Choroidal Neovascularization Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Choroidal Neovascularization Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Choroidal Neovascularization Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Choroidal Neovascularization Market

• 12.1. Australia Choroidal Neovascularization Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Choroidal Neovascularization Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Choroidal Neovascularization Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Choroidal Neovascularization Market

• 13.1. Indonesia Choroidal Neovascularization Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Choroidal Neovascularization Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Choroidal Neovascularization Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Choroidal Neovascularization Market

• 14.1. South Korea Choroidal Neovascularization Market Overview
• 14.2. South Korea Choroidal Neovascularization Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Choroidal Neovascularization Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Choroidal Neovascularization Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Choroidal Neovascularization Market

• 15.1. Western Europe Choroidal Neovascularization Market Overview
• 15.2. Western Europe Choroidal Neovascularization Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Choroidal Neovascularization Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Choroidal Neovascularization Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Choroidal Neovascularization Market

• 16.1. UK Choroidal Neovascularization Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Choroidal Neovascularization Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Choroidal Neovascularization Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Choroidal Neovascularization Market

• 17.1. Germany Choroidal Neovascularization Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Choroidal Neovascularization Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Choroidal Neovascularization Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Choroidal Neovascularization Market

• 18.1. France Choroidal Neovascularization Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Choroidal Neovascularization Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Choroidal Neovascularization Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Choroidal Neovascularization Market

• 19.1. Italy Choroidal Neovascularization Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Choroidal Neovascularization Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Choroidal Neovascularization Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Choroidal Neovascularization Market

• 20.1. Spain Choroidal Neovascularization Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Choroidal Neovascularization Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Choroidal Neovascularization Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Choroidal Neovascularization Market

• 21.1. Eastern Europe Choroidal Neovascularization Market Overview
• 21.2. Eastern Europe Choroidal Neovascularization Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Choroidal Neovascularization Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Choroidal Neovascularization Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Choroidal Neovascularization Market

• 22.1. Russia Choroidal Neovascularization Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Choroidal Neovascularization Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Choroidal Neovascularization Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Choroidal Neovascularization Market

• 23.1. North America Choroidal Neovascularization Market Overview
• 23.2. North America Choroidal Neovascularization Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Choroidal Neovascularization Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Choroidal Neovascularization Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Choroidal Neovascularization Market

• 24.1. USA Choroidal Neovascularization Market Overview
• 24.2. USA Choroidal Neovascularization Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Choroidal Neovascularization Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Choroidal Neovascularization Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Choroidal Neovascularization Market

• 25.1. Canada Choroidal Neovascularization Market Overview
• 25.2. Canada Choroidal Neovascularization Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Choroidal Neovascularization Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Choroidal Neovascularization Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Choroidal Neovascularization Market

• 26.1. South America Choroidal Neovascularization Market Overview
• 26.2. South America Choroidal Neovascularization Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Choroidal Neovascularization Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Choroidal Neovascularization Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Choroidal Neovascularization Market

• 27.1. Brazil Choroidal Neovascularization Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Choroidal Neovascularization Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Choroidal Neovascularization Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Choroidal Neovascularization Market

• 28.1. Middle East Choroidal Neovascularization Market Overview
• 28.2. Middle East Choroidal Neovascularization Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Choroidal Neovascularization Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Choroidal Neovascularization Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Choroidal Neovascularization Market

• 29.1. Africa Choroidal Neovascularization Market Overview
• 29.2. Africa Choroidal Neovascularization Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Choroidal Neovascularization Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Choroidal Neovascularization Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Choroidal Neovascularization Market Competitive Landscape And Company Profiles

• 30.1. Choroidal Neovascularization Market Competitive Landscape
• 30.2. Choroidal Neovascularization Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Roche Holding AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Bayer Aktiengesellschaft Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Novartis AG Overview, Products and Services, Strategy and Financial Analysis

31. Choroidal Neovascularization Market Other Major And Innovative Companies

• 31.1. Teva Pharmaceutical Industries Limited
• 31.2. Regeneron Pharmaceuticals Inc.
• 31.3. Astellas Pharma Inc.
• 31.4. Biogen Inc.
• 31.5. Chugai Pharmaceutical Co. Ltd.
• 31.6. Alcon Inc.
• 31.7. Genentech Inc.
• 31.8. Bausch + Lomb Incorporated
• 31.9. Samsung Bioepis Co. Ltd.
• 31.10. Santen Pharmaceutical Co. Ltd.
• 31.11. Apellis Pharmaceuticals Inc.
• 31.12. Kodiak Sciences Inc.
• 31.13. Xbrane Biopharma AB
• 31.14. Allergan Inc.
• 31.15. Adverum Biotechnologies Inc.

32. Global Choroidal Neovascularization Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Choroidal Neovascularization Market

34. Recent Developments In The Choroidal Neovascularization Market

35. Choroidal Neovascularization Market High Potential Countries, Segments and Strategies

• 35.1 Choroidal Neovascularization Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Choroidal Neovascularization Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Choroidal Neovascularization Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer